Therapeutic targeting of aldosterone: A novel approach to the treatment of glomerular disease

Clinical Science

Volumn 128, Issue 9, 2015, Pages 527-535

  Brem, Andrew S ^a   Gong, Rujun ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Aldosterone; Apoptosis; Glomerulus; Glycogen synthase kinase 3 ; Mesangial cell; Mineralocorticoid receptor; Mitochnodrial dysfunction; Podocyte; Proliferation; Reactive oxygen species

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; MINERALOCORTICOID ANTAGONIST;

APOPTOSIS; CELL PROLIFERATION; GLOMERULOPATHY; HUMAN; MESANGIUM CELL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; FIBROSIS; GLOMERULUS; KIDNEY DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEINURIA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ALDOSTERONE; ANIMALS; DRUG DESIGN; FIBROSIS; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MOLECULAR TARGETED THERAPY; PROTEINURIA; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84951743062     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20140432     Document Type: Review

References (68)

1. Selye, H. (1955) Anticortisol action of aldosterone. Science 121, 368-369
2. Porter, G. A. and Edelman, I.S. (1964) The action of aldosterone and related corticosteroids on sodium transport across the toad bladder. J. Clin. Invest. 43, 611-620
3. Funder, J.W., Feldman, D. and Edelman, I.S. (1973) The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 92, 994-1004
4. Farman, N., Kusch, M. and Edelman, I.S. (1978) Aldosterone receptor occupancy and sodium transport in the urinary bladder of Bufo marinus. Am. J. Physiol. 235, C90-C96
5. Rossier, B.C., Wilce, P.A. and Edelman, I.S. (1977) Spironolactone antagonism of aldosterone action on Na + transport and RNA metabolism in toad bladder epithelium. J. Membr. Biol. 32, 177-194
6. Le Menuet, D., Viengchareun, S., Muffat-Joly, M., Zennaro, M.C. and Lombes, M. (2004) Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Mol. Cell Endocrinol. 217, 127-136
7. Arriza, J.L., Weinberger, C., Cerelli, G., Glaser, T.M., Handelin, B.L., Housman, D.E. and Evans, R.M. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268-275
8. Funder, J.W., Pearce, P.T., Smith, R. and Smith, A.I. (1988) Mineralocorticord action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583-585
9. Funder, J. and Myles, K. (1996) Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137, 5264-5268
10. Brem, A.S., Bina, R.B., King, T. and Morris, D.J. (1995) Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids 60, 406-410
11. Brem, A.S., Bina, R.B., King, T.C. and Morris, D.J. (1998) Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 31, 459-462
12. Hughes, K.A., Manolopoulos, K.N., Iqbal, J., Cruden, N.L., Stimson, R.H., Reynolds, R.M., Newby, D.E., Andrew, R., Karpe, F. and Walker, B.R. (2012) Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 61, 1357-1364
13. Brem, A.S., Bina, R.B., King, T., Chobanian, M.C. and Morris, D.J. (1997) Influence of dietary sodium on the renal isoforms of 11 beta- hydroxysteroid dehydrogenase. Proc. Soc. Exp. Biol. Med. 214, 340-345
14. Brem, A.S., Bina, R.B., Fitzpatrick, C., King, T., Tang, S.S. and Ingelfinger, J.R. (1999) Glucocorticoid metabolism in proximal tubules modulates angiotensin II- induced electrolyte transport. Proc. Soc. Exp. Biol. Med. 221, 111-117
15. Rusvai, E. and Naray-Fejes-Toth, A. (1993) A new isoform of 11 beta-hydroxysteroid dehydrogenase in aldosterone target cells. J. Biol. Chem. 268, 10717-10720
16. Albiston, A.L., Obeyesekere, V.R., Smith, R.E. and Krozowski, Z.S. (1994) Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell Endocrinol. 105, R11-R17
17. Porter, G.A., Bogoroch, R. and Edelman, I.S. (1964) On the mechanism of action of aldosterone on sodium transport: the role of RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 52, 1326-1333
18. Christ, M. and Wehling, M. (1999) Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Steroids 64, 35-41
19. Boldyreff, B. and Wehling, M. (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol. Dial. Transplant. 18, 1693-1695
20. Mihailidou, A.S. and Funder, J.W. (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70, 347-351
21. Wendler, A., Albrecht, C. and Wehling, M. (2012) Nongenomic actions of aldosterone and progesterone revisited. Steroids 77, 1002-1006
22. Terada, Y., Kuwana, H., Kobayashi, T., Okado, T., Suzuki, N., Yoshimoto, T., Hirata, Y. and Sasaki, S. (2008) Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J. Am. Soc. Nephrol. 19, 298-309
23. Aldigier, J.C., Kanjanbuch, T., Ma, L.J., Brown, N.J. and Fogo, A.B. (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol. 16, 3306-3314
24. Brem, A.S., Morris, D.J., Ge, Y., Dworkin, L.D., Tolbert, E. and Gong, R. (2010) Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11β-HSD activity. Am. J. Physiol. Renal. Physiol. 298, F1178-F1187
25. Zhu, C., Huang, S., Yuan, Y., Ding, G., Chen, R., Liu, B., Yang, T. and Zhang, A. (2011) Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am. J. Pathol. 178, 2020-2031, doi: 10.1016/j.ajpath.2011.2001.2029
26. Alzamora, R., Brown, L.R. and Harvey, B.J. (2007) Direct binding and activation of protein kinase C isoforms by aldosterone and 17beta-estradiol. Mol. Endocrinol. 21, 2637-2650
27. Huang, S., Zhang, A., Ding, G. and Chen, R. (2009) Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am. J. Physiol. Renal Physiol. 296, F1323-1333
28. Terada, Y., Ueda, S., Hamada, K., Shimamura, Y., Ogata, K., Inoue, K., Taniguchi, Y., Kagawa, T., Horino, T. and Takao, T. (2012) Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serumand glucocorticoid-inducible protein kinase-1. Clin. Exp. Nephrol. 16, 81-88
29. Shibata, S., Nagase, M., Yoshida, S., Kawachi, H. and Fujita, T. (2007) Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49, 355-364
30. Nagase, M., Yoshida, S., Shibata, S., Nagase, T., Gotoda, T., Ando, K. and Fujita, T. (2006) Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17, 3438-3446
31. Gomez-Sanchez, C.E., de Rodriguez, A.F., Romero, D.G., Estess, J., Warden, M.P., Gomez-Sanchez, M.T. and Gomez-Sanchez, E.P. (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147, 1343-1348
32. Sasano, H., Fukushima, K., Sasaki, I., Matsuno, S., Nagura, H. and Krozowski, Z.S. (1992) Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. J. Endocrinol. 132, 305-310
33. Thomas, W., Dooley, R. and Harvey, B.J. (2010) Aldosterone as a renal growth factor. Steroids 75, 550-554
34. Terada, Y., Kobayashi, T., Kuwana, H., Tanaka, H., Inoshita, S., Kuwahara, M. and Sasaki, S. (2005) Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J. Am. Soc. Nephrol. 16, 2296-2305
35. Greene, E.L., Kren, S. and Hostetter, T.H. (1996) Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068
36. Leroy, V., De Seigneux, S., Agassiz, V., Hasler, U., Rafestin-Oblin, M.E., Vinciguerra, M., Martin, P.Y. and Feraille, E. (2009) Aldosterone activates NF-kappaB in the collecting duct. J. Am. Soc. Nephrol. 20, 131-144
37. Lea, W.B., Kwak, E.S., Luther, J.M., Fowler, S.M., Wang, Z., Ma, J., Fogo, A.B. and Brown, N.J. (2009) Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75, 936-944
38. Lam, E.Y., Funder, J.W., Nikolic-Paterson, D.J., Fuller, P.J. and Young, M.J. (2006) Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats. Endocrinology 147, 3623-3629
39. Rafestin-Oblin, M.E., Couette, B., Barlet-Bas, C., Cheval, L., Viger, A. and Doucet, A. (1991) Renal action of progesterone and 18-substituted derivatives. Am. J. Physiol. 260, F828-832
40. Alberti, K.G. and Sharp, G.W. (1970) Identification of four types of steroid by their interaction with mineralocorticoid receptors in the toad bladder. J. Endocrinol. 48, 563-574
41. Odermatt, A., Arnold, P. and Frey, F.J. (2001) The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J. Biol. Chem. 276, 28484-28492
42. Brem, A.S., Matheson, K.L., Barnes, J.L. and Morris, D.J. (1991) 11-dehydrocorticosterone, a glucocorticoid metabolite, inhibits aldosterone action in toad bladder. Am. J. Physiol. 261, F873-879
43. Vierhapper, H., Derfler, K., Nowotny, P., Hollenstein, U. and Waldhausl, W. (1991) Impaired conversion of cortisol to cortisone in chronic renal insufficiency-a cause of hypertension or an epiphenomenon? Acta Endocrinol. 125, 160-164
44. Brem, A.S., Morris, D.J., Li, X., Ge, Y., Shaw, S. and Gong, R. (2013) Adrenalectomy amplifies aldosterone induced injury in cardiovascular tissue: an effect attenuated by adrenally derived steroids. Steroids 78, 347-355
45. Miyata, K., Rahman, M., Shokoji, T., Nagai, Y., Zhang, G.X., Sun, G.P., Kimura, S., Yukimura, T., Kiyomoto, H., Kohno, M. et al. (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J. Am. Soc. Nephrol. 16, 2906-2912
46. Mathew, J.T., Patni, H., Chaudhary, A.N., Liang, W., Gupta, A., Chander, P.N., Ding, G. and Singhal, P.C. (2008) Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am. J. Physiol. Renal Physiol. 295, F73-F81
47. Brown, N.J. (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 9, 459-469
48. Gauer, S., Segitz, V. and Goppelt-Struebe, M. (2007) Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol. Dial. Transplant 22, 3154-3159
49. Lai, L., Chen, J., Hao, C.M., Lin, S. and Gu, Y. (2006) Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem. Biophys. Res. Commun. 348, 70-75
50. Gaeggeler, H.P., Gonzalez-Rodriguez, E., Jaeger, N.F., Loffing-Cueni, D., Norregaard, R., Loffing, J., Horisberger, J.D. and Rossier, B.C. (2005) Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J. Am. Soc. Nephrol. 16, 878-891
51. Vallon, V., Wyatt, A.W., Klingel, K., Huang, D.Y., Hussain, A., Berchtold, S., Friedrich, B., Grahammer, F., Belaiba, R.S., Gorlach, A. et al. (2006) SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J. Mol. Med. 84, 396-404
52. Su, M., Dhoopun, A.R., Yuan, Y., Huang, S., Zhu, C., Ding, G., Liu, B., Yang, T. and Zhang, A. (2013) Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury. Am. J. Physiol. Renal Physiol. 305, F520-F531
53. Chen, C., Liang, W., Jia, J., van Goor, H., Singhal, P.C. and Ding, G. (2009) Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways. Nephron. Exp. Nephrol. 113, e26-e34
54. Wang, Z., Ge, Y., Bao, H., Dworkin, L., Peng, A. and Gong, R. (2013) Redox-sensitive glycogen synthase kinase 3β-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury. Free. Radic. Biol. Med. 65, 849-858
55. Bao, H., Ge, Y., Zhuang, S., Dworkin, L.D., Liu, Z. and Gong, R. (2012) Inhibition of glycogen synthase kinase-3beta prevents NSAID-induced acute kidney injury. Kidney Int. 81, 662-673
56. Bao, H., Ge, Y., Wang, Z., Zhuang, S., Dworkin, L., Peng, A. and Gong, R. (2014) Delayed administration of a single dose of lithium promotes recovery from AKI. J. Am. Soc. Nephrol. 25, 488-500
57. Moore, T.D., Nawarskas, J.J. and Anderson, J.R. (2003) Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 5, 354-363
58. Armanini, D., Karbowiak, I., Goi, A., Mantero, F. and Funder, J.W. (1985) In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin. Endocrinol. 23, 341-347
59. Ge, R.S., Dong, Q., Sottas, C.M., Latif, S.A., Morris, D.J. and Hardy, M.P. (2005) Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol. Cell. Endocrinol. 243, 35-42
60. Barfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Perez, S., Heckroth, H., Nitsche, A., Erguden, J.K., Gielen-Haertwig, H., Schlemmer, K.H. et al. (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem. Med. Chem. 7, 1385-1403
61. Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.Y. and Zannad, F. (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453-2463
62. Azizi, M., Amar, L. and Menard, J. (2013) Aldosterone synthase inhibition in humans. Nephrol. Dial. Transplant. 28, 36-43, doi: 10.1093/ndt/gfs1388. Epub 2012 Oct 1098
63. Nagase, M., Matsui, H., Shibata, S., Gotoda, T. and Fujita, T. (2007) Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877-883
64. Han, K.H., Kang, Y.S., Han, S.Y., Jee, Y.H., Lee, M.H., Han, J.Y., Kim, H.K., Kim, Y.S. and Cha, D.R. (2006) Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 70, 111-120
65. Bianchi, S., Bigazzi, R. and Campese, V.M. (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116-2123
66. Wang, W., Li, L., Zhou, Z., Gao, J. and Sun, Y. (2013) Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp. Ther. Med. 6, 1527-1531
67. Mehdi, U.F., Adams-Huet, B., Raskin, P., Vega, G.L. and Toto, R.D. (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641-2650
68. Giani, M., Mastrangelo, A., Villa, R., Turolo, S., Marra, G., Tirelli, A.S., Hopfer, H. and Edefonti, A. (2013) Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-beta1. Pediatr. Nephrol. 28, 1837-1842